These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 29381102)
1. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. Gnutzmann D; Kortes N; Sumkauskaite M; Schmitz A; Weiss KH; Radeleff B Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):69-80. PubMed ID: 29381102 [TBL] [Abstract][Full Text] [Related]
2. [Transarterial ablation of hepatocellular carcinoma. Status and developments]. Radeleff BA; Stampfl U; Sommer CM; Bellemann N; Hoffmann K; Ganten T; Ehehalt R; Kauczor HU Radiologe; 2012 Jan; 52(1):44-55. PubMed ID: 22249701 [TBL] [Abstract][Full Text] [Related]
3. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer. Vogl TJ; Gruber-Rouh T Dig Dis Sci; 2019 Apr; 64(4):959-967. PubMed ID: 30835030 [TBL] [Abstract][Full Text] [Related]
4. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. Facciorusso A World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202 [TBL] [Abstract][Full Text] [Related]
5. New concepts in embolotherapy of HCC. Pesapane F; Nezami N; Patella F; Geschwind JF Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645 [TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Post Embolotherapy: Imaging Appearances and Pitfalls on Computed Tomography and Magnetic Resonance Imaging. Chiu RY; Yap WW; Patel R; Liu D; Klass D; Harris AC Can Assoc Radiol J; 2016 May; 67(2):158-72. PubMed ID: 26961737 [TBL] [Abstract][Full Text] [Related]
7. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis. Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. Zou JH; Zhang L; Ren ZG; Ye SL J Dig Dis; 2016 Aug; 17(8):510-517. PubMed ID: 27384075 [TBL] [Abstract][Full Text] [Related]
9. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. Lee EW; Khan S Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030 [TBL] [Abstract][Full Text] [Related]
11. [Survival benefit with intraarterial techniques in hepatocellular carcinoma]. Sangro B Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719 [TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418 [TBL] [Abstract][Full Text] [Related]
13. Chemoembolization and radioembolization. Sangro B Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):909-19. PubMed ID: 25260317 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265 [TBL] [Abstract][Full Text] [Related]
15. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Cucchetti A; Trevisani F; Cappelli A; Mosconi C; Renzulli M; Pinna AD; Golfieri R Dig Liver Dis; 2016 Jul; 48(7):798-805. PubMed ID: 27263056 [TBL] [Abstract][Full Text] [Related]
17. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads. Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307 [TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903 [TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027 [TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. Nam HC; Jang B; Song MJ World J Gastroenterol; 2016 Oct; 22(40):8853-8861. PubMed ID: 27833376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]